Marion reconsidering a move to Puerto Rico?
Executive Summary
While emphasizing that the firm will not make any commitments until the picture on Sec. 936 clears, Marion Exec VP Michael Herman acknowledged that "Puerto Rico certainly is a viable alternative." Herman said the company won't need additional manufacturing capacity for "24 months or so, and hopefully before then the issue will be decided by the Treasury." Herman added that the recent tax simplification proposal from Treasury, in its present form, could add up to $7 mil. to Marion's bottom line if R&D credits remain
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.